## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 3.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Shorepoint Capital Partners LLC Purchases Shares of 35,714 Medtronic PLC $MDT**
- Source: MarketBeat | 20251216T122440 | Bullish | Relevance: 100%
- Shorepoint Capital Partners LLC initiated a new position in Medtronic PLC (NYSE:MDT) during the third quarter, acquiring 35,714 shares valued at approximately $3.40 million. Medtronic recently beat quarterly estimates, announced a quarterly dividend of $0.71, and multiple analysts have raised their price targets on the stock, contributing to a "Moderate Buy" consensus rating.

**2. Thurston Springer Miller Herd & Titak Inc. Sells 24,193 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251217T142645 | Bullish | Relevance: 100%
- Thurston Springer Miller Herd & Titak Inc. significantly reduced its stake in Medtronic PLC, selling 24,193 shares and retaining only 1,912 shares valued at $182,000. Despite this sell-off, Medtronic reported strong Q3 earnings, beating expectations, and announced a quarterly dividend of $0.71 per share. Institutional ownership remains high at 82.06%, and analysts largely maintain a "Moderate Buy" rating with a consensus price target of $110.11.

**3. Northside Capital Management LLC Boosts Stock Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251217T131436 | Bullish | Relevance: 100%
- Northside Capital Management LLC significantly increased its stake in Medtronic PLC by 412.1% in the third quarter, now owning 110,327 shares valued at $10.508 million. This move is part of broader institutional interest, with major investors like Norges Bank and Vanguard also holding substantial shares, bringing total institutional ownership to 82.06%. Medtronic (NYSE: MDT) recently exceeded Q3 earnings expectations, reporting an EPS of $1.36 on revenues of $8.96 billion, and has a "Moderate Buy" consensus rating from analysts with an average price target of $110.11.

**4. Gradient Investments LLC Increases Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251217T092056 | Bullish | Relevance: 100%
- Gradient Investments LLC increased its stake in Medtronic PLC (NYSE:MDT) by 2.6% in the third quarter of 2025, bringing its total holdings to 463,263 shares valued at approximately $44.1 million. This increase comes as Medtronic reported strong quarterly earnings, surpassing analyst estimates with $1.36 EPS and $8.96 billion in revenue, and issued optimistic FY2026 guidance. The stock maintains a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant portion of its shares.

**5. Rep. Julie Johnson Sells Medtronic PLC (NYSE:MDT) Stock**
- Source: MarketBeat | 20251216T080858 | Somewhat-Bullish | Relevance: 100%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Medtronic PLC (NYSE:MDT) stock on November 13th, along with similar-sized sales from other large-cap companies. This sale occurred while Medtronic reported strong quarterly earnings, beating expectations with an EPS of $1.36 and revenue of $8.96 billion, and declared a $0.71 quarterly dividend. Institutional investors hold approximately 82% of MDT stock, and analysts maintain a "Moderate Buy" rating with an average target price of $110.44.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +11%) could attract flows.
- Momentum building: MRS_10 improving +3.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.79 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (8 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $126.1B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.79 |
| Forward P/E | 16.1 |
| Current P/E | 17.4 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.4% to 1.2% (+3.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-0.75), momentum weakening. RSI neutral at 46. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.23% (CS: 37) | Neutral |
| RSI_14 | 45.9 | Neutral |
| MACD Histogram | -0.75 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.079x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $98.31
- **Stop Loss:** $94.85 (3.5% risk)
- **Target:** $101.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 312
- **Position Value:** $30,672.72
- **Portfolio %:** 30.67%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*